OLEMA PHARMACEUTICALS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
OLEMA PHARMACEUTICALS, INC. (OLMA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $12.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Shareholders' Equity › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-10
- OLEMA PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $12.90M, a 175.00% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $10.15M, a 131.80% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $4.25M, a 23.73% decline year-over-year.
- OLEMA PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $4.69M, a 15.34% decline year-over-year.
- OLEMA PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $22.01M, a 30.97% increase from fiscal 2023.
- OLEMA PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $16.80M, a 8.94% decline from fiscal 2022.
- OLEMA PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $18.45M, a 17.68% increase from fiscal 2021.
- OLEMA PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2021 was $15.68M, a 409.42% increase from fiscal 2020.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $12.90M 10-Q · filed 2026-08-10 | $23.05M 10-Q · filed 2026-08-10 | |||
| 2026-03-31 | $10.15M 10-Q · filed 2026-05-12 | ||||
| 2025-09-30 | $4.25M 10-Q · filed 2025-11-10 | $8.94M derived: sum of 2 quarters · filed 2026-08-10 | $13.32M 10-Q · filed 2025-11-10 | $19.51M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-06-30 | $4.69M 10-Q · filed 2026-08-10 | $9.07M 10-Q · filed 2026-08-10 | $15.26M derived: sum of 3 quarters · filed 2026-08-10 | $20.83M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-03-31 | $4.38M 10-Q · filed 2026-05-12 | $4.20M 10-Q · filed 2025-05-13 | $10.57M derived: sum of 2 quarters · filed 2026-05-12 | $16.14M derived: sum of 3 quarters · filed 2026-05-12 | $21.68M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $6.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $11.76M derived: sum of 2 quarters · filed 2026-03-16 | $17.30M derived: sum of 3 quarters · filed 2026-03-16 | $22.01M 10-K · filed 2026-03-16 | |
| 2024-09-30 | $5.57M 10-Q · filed 2025-11-10 | $11.11M derived: sum of 2 quarters · filed 2025-11-10 | $15.82M 10-Q · filed 2025-11-10 | $20.05M derived: sum of 4 quarters · filed 2025-11-10 | |
| 2024-06-30 | $5.54M 10-Q · filed 2025-08-11 | $10.25M 10-Q · filed 2025-08-11 | $14.48M derived: sum of 3 quarters · filed 2025-08-11 | $18.50M derived: sum of 4 quarters · filed 2025-08-11 | |
| 2024-03-31 | $4.70M 10-Q · filed 2025-05-13 | $8.93M derived: sum of 2 quarters · filed 2025-05-13 | $12.95M derived: sum of 3 quarters · filed 2025-05-13 | $16.99M derived: sum of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | $4.23M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $8.25M derived: sum of 2 quarters · filed 2025-03-18 | $12.29M derived: sum of 3 quarters · filed 2025-03-18 | $16.80M 10-K · filed 2025-03-18 | |
| 2023-09-30 | $4.02M 10-Q · filed 2024-11-12 | $8.06M derived: sum of 2 quarters · filed 2024-11-12 | $12.57M 10-Q · filed 2024-11-12 | $17.32M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | $4.04M 10-Q · filed 2024-08-06 | $8.55M 10-Q · filed 2024-08-06 | $13.30M derived: sum of 3 quarters · filed 2024-08-06 | $17.51M derived: sum of 4 quarters · filed 2024-08-06 | |
| 2023-03-31 | $4.51M 10-Q · filed 2024-05-08 | $9.26M derived: sum of 2 quarters · filed 2024-05-08 | $13.47M derived: sum of 3 quarters · filed 2024-05-08 | $18.09M derived: sum of 4 quarters · filed 2024-05-08 | |
| 2022-12-31 | $4.75M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $8.96M derived: sum of 2 quarters · filed 2024-03-11 | $13.58M derived: sum of 3 quarters · filed 2024-03-11 | $18.45M 10-K · filed 2024-03-11 | |
| 2022-09-30 | $4.21M 10-Q · filed 2023-11-07 | $8.83M derived: sum of 2 quarters · filed 2023-11-07 | $13.70M 10-Q · filed 2023-11-07 | $18.24M derived: sum of 4 quarters · filed 2023-11-07 | |
| 2022-06-30 | $4.62M 10-Q · filed 2023-08-08 | $9.50M 10-Q · filed 2023-08-08 | $14.04M derived: sum of 3 quarters · filed 2023-08-08 | $18.16M derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-03-31 | $4.87M 10-Q · filed 2023-05-09 | $9.41M derived: sum of 2 quarters · filed 2023-05-09 | $13.54M derived: sum of 3 quarters · filed 2023-05-09 | $17.41M derived: sum of 4 quarters · filed 2023-05-09 | |
| 2021-12-31 | $4.54M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $8.66M derived: sum of 2 quarters · filed 2023-03-09 | $12.54M derived: sum of 3 quarters · filed 2023-03-09 | $15.68M 10-K · filed 2023-03-09 | |
| 2021-09-30 | $4.13M 10-Q · filed 2022-11-08 | $8.00M derived: sum of 2 quarters · filed 2022-11-08 | $11.14M 10-Q · filed 2022-11-08 | $13.48M derived: sum of 4 quarters · filed 2022-11-08 | |
| 2021-06-30 | $3.87M 10-Q · filed 2022-08-09 | $7.01M 10-Q · filed 2022-08-09 | $9.36M derived: sum of 3 quarters · filed 2022-08-09 | $9.94M derived: sum of 4 quarters · filed 2022-08-09 | |
| 2021-03-31 | $3.14M 10-Q · filed 2022-05-09 | $5.49M derived: sum of 2 quarters · filed 2022-05-09 | $6.07M derived: sum of 3 quarters · filed 2022-05-09 | $6.22M derived: sum of 4 quarters · filed 2022-05-09 | |
| 2020-12-31 | $2.34M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $2.92M derived: sum of 2 quarters · filed 2022-02-28 | $3.08M derived: sum of 3 quarters · filed 2022-02-28 | $3.08M 10-K · filed 2022-02-28 | |
| 2020-09-30 | $582.00K 10-Q · filed 2021-11-10 | $736.00K derived: sum of 2 quarters · filed 2021-11-10 | $736.00K 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $154.00K 10-Q · filed 2021-08-10 | $154.00K 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |